Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9616050 | 0.83 | — | — | |
| SCHEMBL10457153 | 0.73 | CYP2C9 (0.42) | CYP2C9HSD11B1 | |
| SCHEMBL12420559 | 0.69 | CYP2C9 (0.38) | CYP2C9 | |
| SCHEMBL12508912 | 0.69 | CYP2C9 (0.38) | CYP2C9 | |
| SCHEMBL4064503 | 0.69 | CYP2C9 (0.38) | CYP2C9HSD17B10L3MBTL1 | |
| SCHEMBL1726623 | 0.69 | CYP2C9 (0.38) | CYP2C9 | |
| Adamantane SCHEMBL932765 | 0.65 | CYP2C9 (0.32) | CYP2C9 | |
| Adamantane SCHEMBL1931599 | 0.65 | CYP2C9 (0.32) | CYP2C9 | |
| SCHEMBL6444390 | 0.65 | ALDH1A1 (0.35) | — | |
| SCHEMBL31672207 | 0.64 | HSD11B1 (0.40) | CYP2C9HSD11B1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | claimed |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2023-09-28 | — | — | US | claimed |
| EP-4206205-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | Primegene (Beijing) Co., Ltd. (CN) | 2023-07-05 | — | — | EP | claimed |
| EP-3985008-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | Incyte Holdings Corporation (US) | 2022-04-20 | — | — | EP | claimed |
| WO-2022042577-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | 北京普祺医药科技有限公司 | 2022-03-03 | — | — | WO | claimed |
| CN-114085224-A | Preparation method of pyrrolopyrimidine compound | 北京普祺医药科技有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-111875607-B | Preparation method of chiral pyrrolopyrimidine compound | 正大天晴药业集团股份有限公司 | 2021-12-03 | — | — | CN | claimed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | claimed |
| EP-3398952-B1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | claimed |
| EP-3473625-B1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-06-02 | — | — | EP | claimed |
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2014-09-11 | — | — | US | claimed |
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | claimed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | claimed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | claimed |
| US-4336400-A | BRONCHODILATOR AGENTS, CARDIOVASCULAR STIMULANTS | STERLING DRUG INC. (US) | 1982-06-22 | — | — | US | claimed |
| US-RE30241-E | BRONCHODILATION, ADRENERGIC STIMULANTS | STERLING DRUG INC. (US) | 1980-03-25 | — | — | US | claimed |
| US-4153677-A | MICROENCAPSULATED BRONCHODILATOR AGENT, ETHYL CELLULOSE FILM | STERLING DRUG INC. (US) | 1979-05-08 | — | — | US | claimed |
| US-4138581-A | BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS | STERLING DRUGS INC. (US) | 1979-02-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | DPYD, RPLP2, DHPS | CYP2C9 41/4885HSD11B1 2017/4885CA1 4373/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | CYP2C9 583/4885HSD11B1 2157/4885CA1 4808/4885 |
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | CYP2C9 332/4885HSD11B1 888/4885CA1 723/4885 |
| US-20140256941-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | CYP2C9 943/4885HSD11B1 2616/4885CA1 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.